| Dr Yu-fan Zhang, MD | |
|
2811 E 15th St Ste 102, Tulsa, OK 74104-5242 | |
| (918) 935-3240 | |
| (918) 935-3241 |
| Full Name | Dr Yu-fan Zhang |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology - Pain Medicine |
| Location | 2811 E 15th St Ste 102, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134454747 | NPI | - | NPPES |
| Entity Name | Sunil H. Butani Physician P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912169756 PECOS PAC ID: 1850437062 Enrollment ID: O20091001000274 |
News Archive
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.
U.S. Homeland Security Adviser John Brennan on Thursday "hosted a roundtable discussion with World Health Organization (WHO) Director-General Dr. Margaret Chan and senior officials from across the U.S. Government," during which "[p]articipants discussed the steps needed to advance key elements of a U.S. Government-WHO memorandum of understanding on global health security, signed last year on the margins of the United Nations General Assembly," the White House Blog reports.
Cancer, along with heart and vascular disease, is the major cause of death in the Western world. The first generation of anti-cancer drugs has already saved many lives, but because these medicines are non-specific they also often have severe side effects.
The International Contrast Ultrasound Society (ICUS) today applauded the FDA's decision to modify the U.S. product label for OPTISON, an ultrasound contrast agent used to improve the accuracy of radiation-free ultrasound scans.
› Verified 1 days ago
| Entity Name | Hudson Spine And Pain Medicine Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639418858 PECOS PAC ID: 2062647811 Enrollment ID: O20131101000714 |
News Archive
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.
U.S. Homeland Security Adviser John Brennan on Thursday "hosted a roundtable discussion with World Health Organization (WHO) Director-General Dr. Margaret Chan and senior officials from across the U.S. Government," during which "[p]articipants discussed the steps needed to advance key elements of a U.S. Government-WHO memorandum of understanding on global health security, signed last year on the margins of the United Nations General Assembly," the White House Blog reports.
Cancer, along with heart and vascular disease, is the major cause of death in the Western world. The first generation of anti-cancer drugs has already saved many lives, but because these medicines are non-specific they also often have severe side effects.
The International Contrast Ultrasound Society (ICUS) today applauded the FDA's decision to modify the U.S. product label for OPTISON, an ultrasound contrast agent used to improve the accuracy of radiation-free ultrasound scans.
› Verified 1 days ago
| Entity Name | Downtown Pain Medicine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902290661 PECOS PAC ID: 7719207471 Enrollment ID: O20150520000471 |
News Archive
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.
U.S. Homeland Security Adviser John Brennan on Thursday "hosted a roundtable discussion with World Health Organization (WHO) Director-General Dr. Margaret Chan and senior officials from across the U.S. Government," during which "[p]articipants discussed the steps needed to advance key elements of a U.S. Government-WHO memorandum of understanding on global health security, signed last year on the margins of the United Nations General Assembly," the White House Blog reports.
Cancer, along with heart and vascular disease, is the major cause of death in the Western world. The first generation of anti-cancer drugs has already saved many lives, but because these medicines are non-specific they also often have severe side effects.
The International Contrast Ultrasound Society (ICUS) today applauded the FDA's decision to modify the U.S. product label for OPTISON, an ultrasound contrast agent used to improve the accuracy of radiation-free ultrasound scans.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Yu-fan Zhang, MD 2811 E 15th St Ste 102, Tulsa, OK 74104-5242 Ph: (918) 935-3240 | Dr Yu-fan Zhang, MD 2811 E 15th St Ste 102, Tulsa, OK 74104-5242 Ph: (918) 935-3240 |
News Archive
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for the subcutaneous formulation of ORENCIA® (abatacept), a treatment for adult patients with moderate to severe rheumatoid arthritis (RA) administered through an injection into the skin. Bristol-Myers Squibb submitted the sBLA to the FDA for the subcutaneous formulation of ORENCIA and received confirmation of its receipt on October 4, 2010.
U.S. Homeland Security Adviser John Brennan on Thursday "hosted a roundtable discussion with World Health Organization (WHO) Director-General Dr. Margaret Chan and senior officials from across the U.S. Government," during which "[p]articipants discussed the steps needed to advance key elements of a U.S. Government-WHO memorandum of understanding on global health security, signed last year on the margins of the United Nations General Assembly," the White House Blog reports.
Cancer, along with heart and vascular disease, is the major cause of death in the Western world. The first generation of anti-cancer drugs has already saved many lives, but because these medicines are non-specific they also often have severe side effects.
The International Contrast Ultrasound Society (ICUS) today applauded the FDA's decision to modify the U.S. product label for OPTISON, an ultrasound contrast agent used to improve the accuracy of radiation-free ultrasound scans.
› Verified 1 days ago
David Do, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2811 E 15th St Ste 102, Tulsa, OK 74104 Phone: 918-935-3240 Fax: 918-935-3241 | |
Reginald Gene Scott, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 6839 S Canton Ave, Tulsa, OK 74136 Phone: 918-494-0612 | |
Kimberlie K Dullye, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 744 W 9th St, Tulsa, OK 74127 Phone: 918-587-2561 | |
Michelle Pieratt, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1120 S Utica Ave, Tulsa, OK 74104 Phone: 361-949-4976 | |
Judy A Distefano, D.O. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 9423 E 95th Ct, Tulsa, OK 74133 Phone: 918-496-2400 Fax: 918-496-2436 | |
Kenneth Calrisian Reed, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 9320 S Mingo Rd, Tulsa, OK 74133 Phone: 918-901-9701 Fax: 918-901-9702 | |
Dr. Jonathan D Friend, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 4500 S Garnett Rd, Ste 919, Tulsa, OK 74146 Phone: 918-728-6194 Fax: 918-664-2521 |